블로그
- [U.S. FDA] FDA Issues Draft Guidance to Cut Unnecessary Animal Testing for Cancer Drugs draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for certain cancer of animal testing during drug development,” said FDA’s Oncology Center of Excellence Director Angelo de
- Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find ... /6i) have significantly impacted on the treatment of HR + HER2 negative (HER2-) metastatic breast cancer Nonetheless, despite significant research efforts, the mechanisms of de novo and acquired resistance
- A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or ... Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer the cyclin D–cyclin-dependent kinase (CDK)4/6–INK4–retinoblastoma pathway can overcome acquired or de